We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $9.59B
1-Year Est. Return 113.36%
This Fund
S&P 500
This Quarter Est. Return
+17.58%
1 Year Est. Return
+113.36%
3 Year Est. Return
+277.48%
5 Year Est. Return
+350.78%
10 Year Est. Return
+2,290.11%
AUM
$9.59B
AUM Growth
+$1.11B
Cap. Flow
-$1.32B
Cap. Flow %
-13.72%
Top 10 Hldgs %
53.17%
Holding
94
New
11
Increased
13
Reduced
11
Closed
12

Top Buys

Rank Stock Value
1
GMAB icon
Genmab
GMAB
+$117M
2
MLYS icon
Mineralys Therapeutics
MLYS
+$109M
3
BSX icon
Boston Scientific
BSX
+$71.4M
4
PBLS
Parabilis Medicines Inc
PBLS
+$52M
5
IDYA icon
IDEAYA Biosciences
IDYA
+$36.3M

Top Sells

Rank Stock Value
1
COGT icon
Cogent Biosciences
COGT
+$141M
2
CPRX
Catalyst Pharmaceutical
CPRX
+$97.6M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$80.4M
4
DAWN
Day One Biopharmaceuticals
DAWN
+$79.8M
5
EHAB
Enhabit
EHAB
+$66.9M

Sector Composition

Rank Sector Weight
1 Healthcare 83.76%
2 Miscellaneous 16.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DAWN
76
DELISTED
Day One Biopharmaceuticals
DAWN
– –
-3,723,131
Closed -$79.8M
EHAB
77
DELISTED
Enhabit
EHAB
– –
-4,747,746
Closed -$66.9M
KYMR icon
78
Kymera Therapeutics
KYMR
$9.75B
– –
-561,170
Closed -$46.7M
MYGN icon
79
Myriad Genetics
MYGN
$309M
– –
-505
Closed -$2.27K
NBIX icon
80
Neurocrine Biosciences
NBIX
$16.1B
– –
-610,000
Closed -$80.4M
PHGE icon
81
BiomX
PHGE
$3.8M
– –
-131,272
Closed -$493K
QSIAW
82
DELISTED
Quantum-Si Inc Warrant
QSIAW
– –
-333,333
Closed -$36.2K
TSHA icon
83
Taysha Gene Therapies
TSHA
$1.81B
– –
-2,722,165
Closed -$12.2M
MANE
84
Veradermics Inc
MANE
$4.08B
– –
-5,000
Closed -$316K
1 2 3
4

Similar funds

OAM
Oppenheimer Asset Management New York $9.63B AUM 30.32% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
MSE
MUFG Securities EMEA London, United Kingdom $9.53B AUM 52.96% 1-Year Est. Return
VF
Vest Financial Mclean, Virginia $9.52B AUM 31.6% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
A
Allianz Munich, Germany $9.48B AUM 23.58% 1-Year Est. Return
Edgewood Management
Edgewood Management Greenwich, Connecticut $9.69B AUM 6.52% 1-Year Est. Return

Deerfield Management's Q2 2026 Portfolio in Review

As of Q2 2026, Deerfield Management held 94 positions worth $9.59B, up 13% from $8.48B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Deerfield Management withdrew a net $1.32B in Q2 2026, closing 12 positions and reducing 11 holdings. Its most notable exit was Catalyst Pharmaceutical, an estimated $97.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 85% a quarter earlier, followed by Miscellaneous.

Against the trend, Deerfield Management opened a new position in Mineralys Therapeutics worth $107M.

  • Deerfield Management's largest Q2 2026 buy was Mineralys Therapeutics: 3,958,000 shares worth $107M.
  • Deerfield Management added most to Genmab in Q2 2026, an estimated $117M increase.
  • Deerfield Management's biggest Q2 2026 reduction was Cogent Biosciences, cutting an estimated $141M.
  • Deerfield Management fully exited Catalyst Pharmaceutical in Q2 2026, selling an estimated $97.6M.
  • Deerfield Management's ten largest holdings make up 53% of its $9.59B portfolio in Q2 2026.
  • Deerfield Management opened 11 new positions and closed 12 in Q2 2026.
  • Deerfield Management's portfolio value rose 13% quarter-over-quarter to $9.59B.

Based on Deerfield Management's 13F filing for Q2 2026, filed 14 Aug 2026.